Cargando…
The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial
AIMS: To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema. METHODS: Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307641/ https://www.ncbi.nlm.nih.gov/pubmed/25251842 http://dx.doi.org/10.1111/dme.12593 |
_version_ | 1782354466817703936 |
---|---|
author | Scanlon, P H Loftus, J Starita, C Stratton, I M |
author_facet | Scanlon, P H Loftus, J Starita, C Stratton, I M |
author_sort | Scanlon, P H |
collection | PubMed |
description | AIMS: To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema. METHODS: Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control. RESULTS: For all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye. CONCLUSIONS: We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials. |
format | Online Article Text |
id | pubmed-4307641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43076412015-02-04 The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial Scanlon, P H Loftus, J Starita, C Stratton, I M Diabet Med Research Articles AIMS: To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema. METHODS: Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control. RESULTS: For all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye. CONCLUSIONS: We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials. BlackWell Publishing Ltd 2015-01 2014-10-13 /pmc/articles/PMC4307641/ /pubmed/25251842 http://dx.doi.org/10.1111/dme.12593 Text en © 2014 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Scanlon, P H Loftus, J Starita, C Stratton, I M The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
title | The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
title_full | The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
title_fullStr | The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
title_full_unstemmed | The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
title_short | The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
title_sort | use of weighted health-related quality of life scores in people with diabetic macular oedema at baseline in a randomized clinical trial |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307641/ https://www.ncbi.nlm.nih.gov/pubmed/25251842 http://dx.doi.org/10.1111/dme.12593 |
work_keys_str_mv | AT scanlonph theuseofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT loftusj theuseofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT staritac theuseofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT strattonim theuseofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT scanlonph useofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT loftusj useofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT staritac useofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial AT strattonim useofweightedhealthrelatedqualityoflifescoresinpeoplewithdiabeticmacularoedemaatbaselineinarandomizedclinicaltrial |